Strategic Partnerships
Harvard Medical School (HMS) Partnership
Status: Immediate placement offered (December 2025)
Focus: Commercial innovation track for regulatory strategy refinement
Value: Access to HMS clinical network, regulatory expertise, and pilot site identification
Why HMS: Selected over Johns Hopkins University due to Humanoid Healthcare's current priorities for commercialization / Seed Funding
What This Means for Investors:
De-risked execution: Top medical institutions validate our regulatory pathway
Credibility: HMS backing opens doors with FDA reviewers and institutional buyers
Talent pipeline: Access to clinical advisors and pilot partners
Network effects: HMS connection accelerates partnerships with Medical Alley ecosystem (Mayo Clinic, Medtronic)
Market Validation
Our dual-track approach targeting Medical Alley in Minnesota provides access to:
Mayo Clinic
World-class clinical validation partner for pilot programs
Medtronic
Medical device regulatory expertise and manufacturing insights
1,000+ MedTech Companies
Dense ecosystem of medical device innovation and talent
FDA Expertise
Streamlined regulatory pathway for faster market entry
This strategic positioning gives us first-mover advantage in establishing the regulatory standard for humanoid healthcare.